Kyverna Therapeutics Plans FDA Submission for Stiff Person Syndrome Cell Therapy

Kyverna Therapeutics plans to submit its one-time CAR-T cell therapy for stiff person syndrome to the FDA by mid-2026 after late-stage trial results presented on April 21, 2026 showed improvements in mobility and reduced disabilities. The treatment would become the first FDA-approved therapy for stiff person syndrome, a rare neurological autoimmune disorder, and the first personalized CAR-T therapy for any autoimmune disease to reach the market. CAR-T treatments, which use engineered T cells to deplete B cells and reset the immune system, are currently approved only for blood cancers as of April 2026. A growing number of biotech companies have shifted their CAR-T focus to autoimmune diseases, making Kyverna's submission a potential milestone in expanding the technology beyond oncology.

Kyverna's stiff person syndrome cell therapy trial results and FDA submission plans

• ▪Kyverna Therapeutics' stiff person syndrome treatment is a one-time, personalized cell therapy.
• ▪Kyverna Therapeutics' personalized cell therapy improved mobility in patients with stiff person syndrome according to study results presented on April 21, 2026.
• ▪Kyverna Therapeutics' stiff person syndrome treatment would become the first treatment for stiff person syndrome if approved by the FDA.
• ▪Kyverna Therapeutics intends to submit its stiff person syndrome treatment to the Food and Drug Administration by the middle of 2026.
• ▪Stiff person syndrome is a rare, neurological autoimmune disorder.

Expansion of CAR-T therapy from cancer treatment to autoimmune diseases

• ▪CAR-T treatments are currently approved only for blood cancers as of April 2026.
• ▪CAR-T therapy uses engineered T cells to deplete B cells, essentially performing an immune system reset inside a patient.
• ▪A growing number of biotech companies have shifted their CAR-T focus to autoimmune diseases as of April 2026.

Perspective of Kyverna Therapeutics

• ▪Kyverna Therapeutics views the stiff person syndrome treatment as potentially the first approved therapy for the rare disease.
• ▪Kyverna Therapeutics positions its CAR-T therapy as expanding the technology beyond cancer treatment into autoimmune disorders.

Perspective of Stiff person syndrome patients

• ▪Stiff person syndrome patients currently lack FDA-approved treatment options specifically for their condition as of April 2026.
• ▪The one-time nature of Kyverna Therapeutics' CAR-T therapy offers stiff person syndrome patients a potential alternative to ongoing treatment regimens.

Perspective of Biotech industry observers

• ▪The biotech industry sees autoimmune diseases as a new frontier for CAR-T technology previously limited to blood cancers.
• ▪Kyverna Therapeutics' FDA submission could validate the commercial viability of CAR-T therapies for autoimmune conditions.

1 source